Reichert; Paul
Patent Applications and Registrations
Patent applications and USPTO patent grants for Reichert; Paul.The latest application filed is for "anti-human pd-1 antibody crystals and methods of use thereof".
Company Profile
1.29.19
- Reichert; Paul - Montville NJ
- Reichert; Paul - Rochester Hills MI
- Reichert; Paul - Shorthills NJ
Patent Activity
| Patent | Date |
|---|---|
| Anti-human Pd-1 Antibody Crystals And Methods Of Use Thereof App 20210317215 - Reichert; Paul ; et al. | 2021-10-14 |
| Crystals of anti-human PD-1 monoclonal antibodies Grant 11,014,986 - Reichert , et al. May 25, 2 | 2021-05-25 |
| Crystals Of Anti-human Pd-1 Monoclonal Antibodies App 20180237524 - Reichert; Paul ; et al. | 2018-08-23 |
| Crystalline anti-human IL-23p19 antibodies Grant 9,803,010 - Reichert , et al. October 31, 2 | 2017-10-31 |
| Power take-off unit with hydraulic disconnect Grant 9,776,508 - Amerla , et al. October 3, 2 | 2017-10-03 |
| C.difficile toxin B CROP domain peptides, antibodies and complexes thereof Grant 9,181,632 - Murgolo , et al. November 10, 2 | 2015-11-10 |
| Power Take-off Unit With Hydraulic Disconnect App 20150298544 - Amerla; Mario ; et al. | 2015-10-22 |
| Crystalline Anti-human Il-23 Antibodies App 20150147337 - Reichert; Paul ; et al. | 2015-05-28 |
| Factor IXa crystals, related complexes and methods Grant 8,710,188 - Beyer , et al. April 29, 2 | 2014-04-29 |
| Crystal of human interferon alpha 2B in complex with zinc Grant 8,679,472 - Reichert , et al. March 25, 2 | 2014-03-25 |
| Factor IXa Crystals, Related Complexes and Methods App 20130157281 - BEYER; BRIAN M. ; et al. | 2013-06-20 |
| MEK1 polypeptides Grant 8,440,443 - Fischmann , et al. May 14, 2 | 2013-05-14 |
| Kinase domain polypeptide of human protein kinase B gamma (AKT3) Grant 8,088,611 - Prongay , et al. January 3, 2 | 2012-01-03 |
| Crystal of pregnane X receptor fused to steroid receptor coactivator-1 Grant 8,048,663 - Wang , et al. November 1, 2 | 2011-11-01 |
| Polynucleotides encoding soluble, stable forms of human double minute 2 polypeptides Grant 8,034,907 - Taremi , et al. October 11, 2 | 2011-10-11 |
| Factor IXa crystals, related complexes and methods Grant 7,968,683 - Beyer , et al. June 28, 2 | 2011-06-28 |
| HDM2 polypeptides Grant 7,888,474 - Hesson , et al. February 15, 2 | 2011-02-15 |
| Pregnane X Receptor Compositions, Crystals and Uses Thereof App 20100286372 - Wang; Wenyan ; et al. | 2010-11-11 |
| Method for crystallizing aurora 2 kinase catalytic domain polypeptide Grant 7,824,491 - Fischmann , et al. November 2, 2 | 2010-11-02 |
| Hdm2 Polypeptides App 20100267150 - HESSON; THOMAS E. ; et al. | 2010-10-21 |
| Akt3 Polypeptides App 20100267053 - PRONGAY; ANDREW J. ; et al. | 2010-10-21 |
| Pregnane X receptor compositions, crystals and uses thereof Grant 7,785,879 - Wang , et al. August 31, 2 | 2010-08-31 |
| Polynucleotides encoding polypeptide fragments of protein kinase B gamma (AKT3) Grant 7,776,589 - Prongay , et al. August 17, 2 | 2010-08-17 |
| Methods For Crystallizing Erk2 Polypeptides App 20100190231 - ENGLISH; JESSIE M. ; et al. | 2010-07-29 |
| Soluble, Stable Form Of Hdm2, Crystalline Forms Thereof And Methods Of Use Thereof App 20100136620 - Taremi; Shahriar Shane ; et al. | 2010-06-03 |
| Methods for crystallizing ERK2 polypeptides Grant 7,722,718 - English , et al. May 25, 2 | 2010-05-25 |
| HDM2 Polypeptides Grant 7,705,127 - Hesson , et al. April 27, 2 | 2010-04-27 |
| Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof Grant 7,632,920 - Taremi , et al. December 15, 2 | 2009-12-15 |
| Crystalline Form Of The Catalytic Domain Of Aurora 2 Kinase And Methods Of Use Thereof App 20090081706 - Fischmann; Thierry O. ; et al. | 2009-03-26 |
| Hepatitis C virus NS3 helicase subdomain I Grant 7,459,296 - Weber , et al. December 2, 2 | 2008-12-02 |
| Crystalline form of the catalytic domain of Aurora 2 kinase and methods of use thereof Grant 7,422,885 - Fischmann , et al. September 9, 2 | 2008-09-09 |
| Erk2 Crystals App 20080081360 - English; Jessie ; et al. | 2008-04-03 |
| ERK2 crystals Grant 7,312,061 - English , et al. December 25, 2 | 2007-12-25 |
| Crystalline form of an n231 mutant catalytic domain of ADAM33 and methods of use thereof Grant 7,285,408 - Orth , et al. October 23, 2 | 2007-10-23 |
| ERK2 crystals App 20060088924 - English; Jessie ; et al. | 2006-04-27 |
| Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof App 20050037383 - Taremi, Shahriar Shane ; et al. | 2005-02-17 |
| Hepatitis C virus NS3 helicase fragments App 20040253577 - Weber, Patricia C. ; et al. | 2004-12-16 |
| Crystalline form of the catalytic domain of ADAM33 and methods of use thereof App 20040157309 - Orth, Peter ; et al. | 2004-08-12 |
| Beta-secretase crystals and methods for preparing and using the same App 20040014194 - Beyer, Brian M. ; et al. | 2004-01-22 |
| Crystalline interferon alpha for pulmonary delivery and method for producing the same Grant 5,972,331 - Reichert , et al. October 26, 1 | 1999-10-26 |
| Method for producing metal-interferon-.alpha. crystals Grant 5,602,232 - Reichert , et al. February 11, 1 | 1997-02-11 |
| Metal-interferon-alpha crystals Grant 5,441,734 - Reichert , et al. August 15, 1 | 1995-08-15 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 